Hangzhou
First Affiliated Hospital, Zhejiang University
浙江大学医学院附属第一医院
- Grade 3A
Key specialties: Gastroenterology & Hepatology · Oncology · Hematology & CAR-T
View hospital profile
Hematology & CAR-T · Treatment
CAR-T Therapy in China
Access to NMPA-approved CAR-T cell therapies or registered clinical trials for selected blood cancers, with eligibility decided by the hospital.
- Hematology & CAR-T
- Typical stay: Often 6–10 weeks near the hospital in total; the hospital confirms the schedule
- 6 hospitals in 5 cities
Last reviewed October 20, 2026
Is CAR-T therapy in China right for you?
CAR-T cell therapy is a personalized immunotherapy in which the patient's own T cells are collected, engineered to recognize cancer cells, and infused back. In China it is available as products approved by the National Medical Products Administration (NMPA) — currently for specific B-cell lymphomas, B-cell acute lymphoblastic leukemia and multiple myeloma indications — or within registered clinical trials.
It is generally considered for patients whose blood cancer has relapsed or not responded to earlier lines of treatment. Whether a patient is eligible depends on the diagnosis, previous treatments, current disease status and overall health, and is decided by the hospital's hematology team. Horcare coordinates access only to approved products or registered trials.
Final eligibility is decided by the treating hospital after reviewing your records.
What the hospital will usually need to review
- Your most recent specialist letter or discharge summary
- Imaging reports, plus the original image files where possible
- Pathology or biopsy reports, if any
- Treatment history and dates
- Current medications and allergies
Any language is fine; translation is arranged during the review.
Submit medical reportsWhy patients consider China for CAR-T therapy
- Approved products. The NMPA has approved several CAR-T products for specific B-cell lymphomas, leukemia and multiple myeloma indications.
- Clinical research activity. China runs a large number of registered cell-therapy trials; trial participation always depends on the trial's own criteria.
- Large hematology departments. Major Grade 3A hospitals in Beijing, Shanghai, Hangzhou and Wuhan run hematology departments experienced in transplant-level supportive care.
Waiting times vary by hospital and are confirmed during the case review. Horcare matches by department strength for the condition, not by how famous a hospital is.
Step by step
Your CAR-T therapy journey
Coordination steps are handled by Horcare; clinical steps are run entirely by the hospital.
How long you'll stay
Often 6–10 weeks near the hospital in total; the hospital confirms the schedule. The hospital confirms the timeline after its review.
Plan for a companion, accommodation near the hospital and interpreter support. Visa rules change: confirm with the Chinese embassy or visa center.
- 01
Free case review
You send recent reports and imaging. Horcare replies personally within 24 hours and gives an initial assessment of suitable hospitals and departments within 72 hours.
- 02
Hematology eligibility review
Hospital hematologists review pathology, prior treatment lines and recent test results to judge whether an approved product or an open registered trial fits.
- 03
Visa and travel
Horcare coordinates the hospital documents needed for your visa application, airport pickup and accommodation near the hospital. Confirm visa requirements with the Chinese embassy or visa center.
- 04
Work-up and cell collection
On arrival, tests confirm fitness for treatment and T cells are collected by apheresis. Manufacturing then takes several weeks, sometimes with bridging therapy.
- 05
Infusion and monitoring
After conditioning chemotherapy the cells are infused, followed by close in-hospital and nearby monitoring for side effects such as cytokine release syndrome.
- 06
Return home and follow-up
You leave with translated discharge records. Horcare coordinates remote follow-up with the treating doctor and any return visits.
Cost
Cost of CAR-T therapy in China
Indicative hospital costs for CAR-T therapy in China are RMB 0.999–1.29 million list price for the CAR-T product, per infusion (about US$140,000–181,000), confirmed by the hospital's written quote.
| What | Who you pay | Amount |
|---|---|---|
| Hospital charges (consultations, tests, procedure, ward, medicines) | Paid directly to the hospital | RMB 0.999–1.29 million list price for the CAR-T product, per infusion (about US$140,000–181,000) — indicative, confirmed by the hospital's quote |
| Horcare coordination fee | Paid to Horcare, quoted in writing first | Quoted after your free case review |
| Travel and accommodation for patient and companion | Booked by you, with our help | Depends on city and length of stay |
| Initial case review | — | Free |
Source: Launch list prices of NMPA-approved CAR-T products, as tabulated in Zheng S-L, Zhang X-Q, International Journal of Health Policy and Management, 2024 (PMC11365067). Hospital stay, tests, chemotherapy and supportive care are billed separately.
For reference, United States: the 2025 US list price (wholesale acquisition cost) of the CAR-T product alone was $503,580 for axicabtagene ciloleucel (Yescarta) and $593,533 for tisagenlecleucel (Kymriah), according to Pulice and Schulman, Health Management, Policy and Innovation, 2026. Hospital and monitoring costs come on top.
These figures are product list prices, not the total cost of treatment, and products and approved indications differ between countries. Eligibility is decided by the treating hospital, and the hospital's written quote is the figure that applies to you.
What a hospital estimate usually covers
- Pre-treatment tests and work-up
- The procedure, product or treatment course
- The hospital stay and ward type
- Medicines during the stay
What can change the final bill
- Additional tests the doctors request
- Complications or a longer stay
- International department versus general ward pricing
- A revised plan, always re-quoted by the hospital first
The case review is free, hospital bills are paid directly to the hospital with no markup, and Horcare's service fee is quoted in writing before any paid work. How payment works.
Request a free case reviewHospitals
Hospitals we help patients access for CAR-T therapy
These hospitals have departments that provide CAR-T therapy. Listed alphabetically, not ranked; the right one depends on your diagnosis.
Guangzhou
Nanfang Hospital
南方医科大学南方医院
- Grade 3A
Key specialties: Oncology · Gastroenterology & Hepatology · Nephrology & Urology
View hospital profile
Beijing
Peking Union Medical College Hospital
北京协和医院
- Grade 3A
- International department
Key specialties: Oncology · Hematology & CAR-T · Cardiology & Cardiac Surgery
View hospital profile
Shanghai
Ruijin Hospital
上海瑞金医院
- Grade 3A
Key specialties: Hematology & CAR-T · Oncology · Cardiology & Cardiac Surgery
View hospital profile
Wuhan
Tongji Hospital
华中科技大学同济医学院附属同济医院
- Grade 3A
Key specialties: Oncology · Hematology & CAR-T · Gastroenterology & Hepatology
View hospital profile
Wuhan
Union Hospital, Tongji Medical College
华中科技大学同济医学院附属协和医院
- Grade 3A
Key specialties: Oncology · Hematology & CAR-T · Cardiology & Cardiac Surgery
View hospital profile
Where you can have CAR-T therapy in China
How Horcare supports you
One dedicated bilingual coordinator works with you from the first inquiry to follow-up at home, supported by medical interpreters at consultations, admission and discharge.
You get a personal reply within 24 hours and an initial assessment within 72 hours. Hospital charges are kept separate from the coordination fee, and every clinical decision stays with the hospital. See how it works or read about Horcare.
Frequently asked questions
Is CAR-T therapy approved in China?
Yes. China's National Medical Products Administration has approved several CAR-T products for specific blood cancer indications. Other uses are only available through registered clinical trials with their own entry criteria.
Who decides if I am eligible for CAR-T?
The hospital's hematology team decides, after reviewing your diagnosis, previous treatments and current condition. Horcare cannot promise eligibility or results.
Does Horcare arrange stem cell therapy?
Only approved products or registered clinical trials. Horcare does not coordinate unapproved cell or stem cell treatments.
How much does CAR-T therapy in China cost?
Horcare does not publish a price list. The cost depends on the diagnosis, the hospital and the treatment plan, so the hospital gives its own quote after reviewing your records. You pay the hospital directly with no markup from Horcare; our coordination fee is quoted in writing before any paid work. Pricing is quoted after your free case review.
Not sure if CAR-T therapy in China is right for you?
Share the diagnosis and we'll reply personally within 24 hours. No passport or full records needed to start.
No passport or full records needed to start · Hospital bills paid directly to the hospital, no markup